Richard Heidebrecht Email & Phone Number

Beverly, Massachusetts, Us

Glycologix is a glycobiologics company developing novel biomimetic proteoglycan materials with the potential to provide ground-breaking therapeutic solutions to soft tissue repair. The company has both raised seed funding and has been awarded a Phase II SBIR grant from the NIH. Our phase 1 clinical trial in patients with Interstitial Cystitis/Bladder Pain Syndrome is nearing completion.• Positioning the manufacturing, regulatory, and patient engagement strategy for our current clinical trial.• Key contributor to securing seed and bridge raises of ~$6 million.• Scaled up a multistage polymer synthesis In collaboration with a key contract manufacturing organization under GMP to support a clinical trial. • Worked with our academic collaborators to both select a clinical candidate based on phenotypic in vivo experiments and demonstrated superiority of our lead over the standard of care with a novel in vivo binding model.• Created a next generation polymer synthesis strategy that led to novel materials and new intellectual property; quadrupled the productivity of our internal laboratory.• Expanding our platform technology into new indications while remaining focused on our first clinical trial.

Our technology combines the alpha emitter Astatine with multivalent single-domain antibodies to destroy target tumors. More effective targeting with a well behaved alpha emitter will result in superior toxicity profiles for patients. These drugs will work as monotherapies or in combination with contemporary immuno oncology.

Boston, Massachusetts, Us

• Development of leads from phenotypic assays resulted in a new biochemical mechanism to target malaria infections. • Collaboration has provided expanded expertise in drug resistance, fitness cost, and genome-wide association studies.• Consultant on chemistry in infectious and neglected tropical diseases.

• Key leader of multiple advances in delivery of durable cell therapies that directly lead to $155 million in additional funding. Achieved a completed CTA and IND filings and an Orphan Drug Designation from the FDA.• Built strong relationships of collaboration and trust with a multidisciplinary group of colleagues (chemists, biologists, engineers, in vivo team, operations, and key external organizations) resulting in rapid advancement to clinical trial entry.• Developed and executed creative strategies to collaboratively achieve company goals while addressing key liabilities before they become problems.• Increased the in vivo protein productivity (>10x) of implanted cell therapies by optimizing the contacting polymer matrix; discoveries were incorporated into clinical assets and several patent applications.• Created and led an analytical chemistry group that combined an effective mixture of internal and external assets. Two novel assays were created to address key company needs resulting in two patent applications and successful transfers to a contract manufacturing organization.• Established and managed the in vivo, operations, safety, quality, and construction functions. Activities included coordination of collaborative company-wide projects, recruiting and creating a professional company culture.• Optimized and developed an academic, bench-scale discovery from a five-week procedure into a two-day, 100x scale process completed under GMP oversight at a contract manufacturing organization. • Successfully completed the technology transfer and development of the synthesis of an energetic small molecule under GMP oversight while mitigating an unexpected exotherm and solving a challenging purification. • Designed the architecture and implemented a heavily cross-disciplinary electronic laboratory notebook and data management strategy that governed how materials were tracked both internally and externally.

Cambridge, Ma, Us

• Managed a highly successful collaboration with Monsanto that raised $21 million in three separate rounds of funding.• Recruited a multidisciplinary team of synthetic and analytical chemists, computational support, and automation specialists that exceeded the original goals set forth by the research plan.• Led the teams that both designed and created an electronic notebook, registration system and automated liquid handling for combinatorial formulation development; this enabled the automated preparation of over 23,000 mixtures in a few months that were tested by collaborators.• Developed novel strategies to deliver RNA in agriculture, leading to five patent applications.• Generated, tested, and advanced novel ideas by creating a successful think-tank environment that coupled laboratory work, patent filings, and communication with investors.• Invited speaker and author in the use of siRNA in agriculture.• Broad knowledge of the safety, regulatory, and informatics issues associated with operating a small company.

• Designed and prepared a portfolio of novel Fluoropeutics® as investigational new drugs, leading to three patents.• Key molecule SF0166 entered human trials for age-related macular degeneration and diabetic macular edema.• Built expertise in therapeutic areas, such as ophthalmology, pain, neurodegeneration, and anti-infectives.• Worked with colleagues at CROs in both chemistry and biology to meet program goals.• Managed the successful build out of laboratory space, exceeding both timelines and budget.

Cambridge, Ma, Us

• Project leader coordinating the activities of five chemists in collaboration with industrial, academic, and fee-for-service partners.• Optimized novel probe molecules in a phenotypic setting; determined biochemical mechanism of action via resistance selection.• Key driver of additional ~2 million in funding from the Gates Foundation.

• Spearheaded an oncology program that grew to 12 chemists and resulted in a preclinical candidate.• Contributed to four preclinical candidates in the fields of oncology and neuroscience. • Managed the activities of four employees: two on site and two from an outsourcing partner.• Advanced supporter of in silico tools; a key data mining experiment led to an improvement of our in vitro to in vivo success rate from 35% to 52%.• Merck Award for Excellence for leadership in laboratory safety.

New York, New York, Us

Team member of the EGFR inhibitor project that delivered Tarceva® for the treatment of lung and pancreatic cancers.

Postdoc, Organic Chemistry

Ph.D., Organic And Biological Chemistry

B.S, Organic Chemistry